A three-year supply agreement has been entered into by Optibiotix, a life sciences company, and Galenicum Special Ingredients to commercialise products for health concerns such as high blood pressure and cholesterol.
Agreement
Under the terms of the agreement, Galenicum will have a non-exclusive licence to commercialise Cardiocare — a nutritional supplement containing OptiBiotix’s LP-LDL — in the Middle East, Chile, Peru and Spain. This supplement will join Galenicum’s STOP&GO product range for the treatment of issues such as high blood pressure and cholesterol.
“This is an exciting partnership that will enable the mass commercialisation of LP-LDL in Cardiocare for target consumer and pharmaceutical health care markets. We selected Galenicum for its outstanding reputation as a pharmaceutical industry leader, impressive sales growth record and access to markets we have yet to explore,” said Stephen O’Hara, Optibiotix CEO. “By combining our expertise in microbiome modulation with Galenicum’s international renown, manufacturing capacity and scale, we will make LP-LDL a leading global brand and lead the way in harnessing microbiome product development for addressing a range of health problems.”
OptiBiotix’s LP-LDL is a third-generation bacterial strain and probiotic that aids elements of cardiovascular and physiological wellbeing by modulating the human microbiome. The company reports it has been shown in randomised controlled human studies to be safe and well tolerated by human subjects.